Spine Biologics Market By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix) , By End User (Hospitals, Outpatient Facilities) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Spine Biologics Market
The spine biologics market was valued at $3.05 billion in 2023 and is estimated to reach $5.55 billion by 2035, exhibiting a CAGR of 5.29% from 2024 to 2035.
Spine biologics comprises of materials that enhance spinal fusion, promote healing, and treat several spinal disorders. The materials involve growth factors, stem cells, and bone grafts, which help in the natural healing processes of the body. Bone grafts are the scaffolds required for new bone growth. They include autografts, which belong to patient’s own body, and allografts, which are derived from a donor. Stem cells are a special form of cells that have the ability to generate new cells with complete functionalities and growth factors, such as bone morphogenetic proteins (BMPs), play role in stimulating the cells for regeneration and bone repair. The usage of spine biologics is widespread in spinal fusion surgeries, which involve the joining of two or more vertebrae.
Increase in the prevalence of spinal disorders, particularly in the exponentially growing geriatric population, is a key driver of the spine biologics market. In addition, with rising inclination toward minimally invasive procedures, the demand for spine biologics is surging as they facilitate minimal invasion during spinal surgeries and promote healing. In recent times, the use of additive manufacturing for the development of bone graft substitute is an emerging trend in the market. These substitutes offer equivalent efficacy and improved safety when compared to bone grafts, which hold the potential for rejection by the body.
However, the development of spine biologics is a complex procedure with high expenses, hence restraining the development of the market. Furthermore, the ineffective reimbursement policies that do not offer adequate cover for spinal surgeries deter individuals from undergoing expensive treatments, hence limiting the market growth. On the contrary, the consistently rising numbers of spinal injuries are anticipated to propel the demand for spine biologics in the future. The National Library of Medicine recently published an article which reported that every year 38% of new spinal cord injuries occur due to motor vehicular crashes in the U.S. falling is the second most prevalent reason for spinal injuries, accounting for 30% of the total count.
Segment Review
The spine biologics market is segmented into product, end user, and region. By product, the market is divided into spinal allografts, bone graft substitutes, and cell-based matrix. As per end user, it is bifurcated into hospitals and outpatient facilities. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By product, the spinal allografts segment dominated the market in 2023.
As per end user, the hospital segment acquired a high stake in the market in 2023.
Region wise, North America is projected to be the highest revenue generator by 2035.
Competition Analysis
The major players operating in the spine biologics market are Stryker, NuVasive, Inc., Orthofix, Johnson & Johnson, Exactech, Inc., Zimmer Biomet. Arthrex, Inc., Medtronic Plc, Organogenesis Inc., and Kuros Biosciences. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Key Market Segments
By Product
Spinal Allografts
Bone Graft Substitutes
Cell-Based Matrix
By End User
Hospitals
Outpatient Facilities
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Stryker Corporation
NuVasive, Inc.
orthofix
Johnson & Johnson
Exactech, Inc
Zimmer Biomet Holding, Inc.
Arthrex, Inc.
Medtronic plc
Organogenesis Inc
Kuros Biosciences
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: SPINE BIOLOGICS MARKET, BY PRODUCT
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Product
- 4.2. Spinal Allografts
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Bone Graft Substitutes
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Cell-Based Matrix
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- CHAPTER 5: SPINE BIOLOGICS MARKET, BY END USER
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By End User
- 5.2. Hospitals
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Outpatient Facilities
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- CHAPTER 6: SPINE BIOLOGICS MARKET, BY REGION
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Region
- 6.2. North America
- 6.2.1. Key Market Trends and Opportunities
- 6.2.2. Market Size and Forecast, By Product
- 6.2.3. Market Size and Forecast, By End User
- 6.2.4. Market Size and Forecast, By Country
- 6.2.5. U.S. Spine Biologics Market
- 6.2.5.1. Market Size and Forecast, By Product
- 6.2.5.2. Market Size and Forecast, By End User
- 6.2.6. Canada Spine Biologics Market
- 6.2.6.1. Market Size and Forecast, By Product
- 6.2.6.2. Market Size and Forecast, By End User
- 6.2.7. Mexico Spine Biologics Market
- 6.2.7.1. Market Size and Forecast, By Product
- 6.2.7.2. Market Size and Forecast, By End User
- 6.3. Europe
- 6.3.1. Key Market Trends and Opportunities
- 6.3.2. Market Size and Forecast, By Product
- 6.3.3. Market Size and Forecast, By End User
- 6.3.4. Market Size and Forecast, By Country
- 6.3.5. Germany Spine Biologics Market
- 6.3.5.1. Market Size and Forecast, By Product
- 6.3.5.2. Market Size and Forecast, By End User
- 6.3.6. France Spine Biologics Market
- 6.3.6.1. Market Size and Forecast, By Product
- 6.3.6.2. Market Size and Forecast, By End User
- 6.3.7. UK Spine Biologics Market
- 6.3.7.1. Market Size and Forecast, By Product
- 6.3.7.2. Market Size and Forecast, By End User
- 6.3.8. Italy Spine Biologics Market
- 6.3.8.1. Market Size and Forecast, By Product
- 6.3.8.2. Market Size and Forecast, By End User
- 6.3.9. Spain Spine Biologics Market
- 6.3.9.1. Market Size and Forecast, By Product
- 6.3.9.2. Market Size and Forecast, By End User
- 6.3.10. Rest Of Europe Spine Biologics Market
- 6.3.10.1. Market Size and Forecast, By Product
- 6.3.10.2. Market Size and Forecast, By End User
- 6.4. Asia-Pacific
- 6.4.1. Key Market Trends and Opportunities
- 6.4.2. Market Size and Forecast, By Product
- 6.4.3. Market Size and Forecast, By End User
- 6.4.4. Market Size and Forecast, By Country
- 6.4.5. Japan Spine Biologics Market
- 6.4.5.1. Market Size and Forecast, By Product
- 6.4.5.2. Market Size and Forecast, By End User
- 6.4.6. China Spine Biologics Market
- 6.4.6.1. Market Size and Forecast, By Product
- 6.4.6.2. Market Size and Forecast, By End User
- 6.4.7. Australia Spine Biologics Market
- 6.4.7.1. Market Size and Forecast, By Product
- 6.4.7.2. Market Size and Forecast, By End User
- 6.4.8. India Spine Biologics Market
- 6.4.8.1. Market Size and Forecast, By Product
- 6.4.8.2. Market Size and Forecast, By End User
- 6.4.9. South Korea Spine Biologics Market
- 6.4.9.1. Market Size and Forecast, By Product
- 6.4.9.2. Market Size and Forecast, By End User
- 6.4.10. Rest of Asia-Pacific Spine Biologics Market
- 6.4.10.1. Market Size and Forecast, By Product
- 6.4.10.2. Market Size and Forecast, By End User
- 6.5. LAMEA
- 6.5.1. Key Market Trends and Opportunities
- 6.5.2. Market Size and Forecast, By Product
- 6.5.3. Market Size and Forecast, By End User
- 6.5.4. Market Size and Forecast, By Country
- 6.5.5. Brazil Spine Biologics Market
- 6.5.5.1. Market Size and Forecast, By Product
- 6.5.5.2. Market Size and Forecast, By End User
- 6.5.6. Saudi Arabia Spine Biologics Market
- 6.5.6.1. Market Size and Forecast, By Product
- 6.5.6.2. Market Size and Forecast, By End User
- 6.5.7. South Africa Spine Biologics Market
- 6.5.7.1. Market Size and Forecast, By Product
- 6.5.7.2. Market Size and Forecast, By End User
- 6.5.8. Rest of LAMEA Spine Biologics Market
- 6.5.8.1. Market Size and Forecast, By Product
- 6.5.8.2. Market Size and Forecast, By End User
- CHAPTER 7: COMPETITIVE LANDSCAPE
- 7.1. Introduction
- 7.2. Top Winning Strategies
- 7.3. Product Mapping Of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top Player Positioning, 2023
- CHAPTER 8: COMPANY PROFILES
- 8.1. Stryker Corporation
- 8.1.1. Company Overview
- 8.1.2. Key Executives
- 8.1.3. Company Snapshot
- 8.1.4. Operating Business Segments
- 8.1.5. Product Portfolio
- 8.1.6. Business Performance
- 8.1.7. Key Strategic Moves and Developments
- 8.2. NuVasive, Inc.
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Operating Business Segments
- 8.2.5. Product Portfolio
- 8.2.6. Business Performance
- 8.2.7. Key Strategic Moves and Developments
- 8.3. Orthofix
- 8.3.1. Company Overview
- 8.3.2. Key Executives
- 8.3.3. Company Snapshot
- 8.3.4. Operating Business Segments
- 8.3.5. Product Portfolio
- 8.3.6. Business Performance
- 8.3.7. Key Strategic Moves and Developments
- 8.4. Johnson And Johnson
- 8.4.1. Company Overview
- 8.4.2. Key Executives
- 8.4.3. Company Snapshot
- 8.4.4. Operating Business Segments
- 8.4.5. Product Portfolio
- 8.4.6. Business Performance
- 8.4.7. Key Strategic Moves and Developments
- 8.5. Exactech, Inc
- 8.5.1. Company Overview
- 8.5.2. Key Executives
- 8.5.3. Company Snapshot
- 8.5.4. Operating Business Segments
- 8.5.5. Product Portfolio
- 8.5.6. Business Performance
- 8.5.7. Key Strategic Moves and Developments
- 8.6. Zimmer Biomet Holding, Inc.
- 8.6.1. Company Overview
- 8.6.2. Key Executives
- 8.6.3. Company Snapshot
- 8.6.4. Operating Business Segments
- 8.6.5. Product Portfolio
- 8.6.6. Business Performance
- 8.6.7. Key Strategic Moves and Developments
- 8.7. Arthrex, Inc.
- 8.7.1. Company Overview
- 8.7.2. Key Executives
- 8.7.3. Company Snapshot
- 8.7.4. Operating Business Segments
- 8.7.5. Product Portfolio
- 8.7.6. Business Performance
- 8.7.7. Key Strategic Moves and Developments
- 8.8. Medtronic Plc
- 8.8.1. Company Overview
- 8.8.2. Key Executives
- 8.8.3. Company Snapshot
- 8.8.4. Operating Business Segments
- 8.8.5. Product Portfolio
- 8.8.6. Business Performance
- 8.8.7. Key Strategic Moves and Developments
- 8.9. Organogenesis Inc
- 8.9.1. Company Overview
- 8.9.2. Key Executives
- 8.9.3. Company Snapshot
- 8.9.4. Operating Business Segments
- 8.9.5. Product Portfolio
- 8.9.6. Business Performance
- 8.9.7. Key Strategic Moves and Developments
- 8.10. Kuros Biosciences
- 8.10.1. Company Overview
- 8.10.2. Key Executives
- 8.10.3. Company Snapshot
- 8.10.4. Operating Business Segments
- 8.10.5. Product Portfolio
- 8.10.6. Business Performance
- 8.10.7. Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1. GLOBAL SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 2. SPINE BIOLOGICS MARKET FOR SPINAL ALLOGRAFTS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. SPINE BIOLOGICS MARKET FOR BONE GRAFT SUBSTITUTES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. SPINE BIOLOGICS MARKET FOR CELL-BASED MATRIX, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 5. GLOBAL SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 6. SPINE BIOLOGICS MARKET FOR HOSPITALS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. SPINE BIOLOGICS MARKET FOR OUTPATIENT FACILITIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 8. SPINE BIOLOGICS MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 9. NORTH AMERICA SPINE BIOLOGICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 10. NORTH AMERICA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 11. NORTH AMERICA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 12. U.S. SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 13. U.S. SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 14. CANADA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 15. CANADA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 16. MEXICO SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 17. MEXICO SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 18. EUROPE SPINE BIOLOGICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 19. EUROPE SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 20. EUROPE SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 21. GERMANY SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 22. GERMANY SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 23. FRANCE SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 24. FRANCE SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 25. UK SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 26. UK SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 27. ITALY SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 28. ITALY SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 29. SPAIN SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 30. SPAIN SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 31. REST OF EUROPE SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 32. REST OF EUROPE SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 33. ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 34. ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 35. ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 36. JAPAN SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 37. JAPAN SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 38. CHINA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 39. CHINA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 40. AUSTRALIA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 41. AUSTRALIA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 42. INDIA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 43. INDIA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 44. SOUTH KOREA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 45. SOUTH KOREA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 46. REST OF ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 47. REST OF ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 48. LAMEA SPINE BIOLOGICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 49. LAMEA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 50. LAMEA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 51. BRAZIL SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 52. BRAZIL SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 53. SAUDI ARABIA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 54. SAUDI ARABIA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 55. SOUTH AFRICA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 56. SOUTH AFRICA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 57. REST OF LAMEA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 58. REST OF LAMEA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 59. STRYKER CORPORATION: KEY EXECUTIVES
- TABLE 60. STRYKER CORPORATION: COMPANY SNAPSHOT
- TABLE 61. STRYKER CORPORATION: OPERATING SEGMENTS
- TABLE 62. STRYKER CORPORATION: PRODUCT PORTFOLIO
- TABLE 63. STRYKER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 64. NUVASIVE, INC.: KEY EXECUTIVES
- TABLE 65. NUVASIVE, INC.: COMPANY SNAPSHOT
- TABLE 66. NUVASIVE, INC.: OPERATING SEGMENTS
- TABLE 67. NUVASIVE, INC.: PRODUCT PORTFOLIO
- TABLE 68. NUVASIVE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 69. ORTHOFIX: KEY EXECUTIVES
- TABLE 70. ORTHOFIX: COMPANY SNAPSHOT
- TABLE 71. ORTHOFIX: OPERATING SEGMENTS
- TABLE 72. ORTHOFIX: PRODUCT PORTFOLIO
- TABLE 73. ORTHOFIX: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 74. JOHNSON AND JOHNSON: KEY EXECUTIVES
- TABLE 75. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
- TABLE 76. JOHNSON AND JOHNSON: OPERATING SEGMENTS
- TABLE 77. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
- TABLE 78. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 79. EXACTECH, INC: KEY EXECUTIVES
- TABLE 80. EXACTECH, INC: COMPANY SNAPSHOT
- TABLE 81. EXACTECH, INC: OPERATING SEGMENTS
- TABLE 82. EXACTECH, INC: PRODUCT PORTFOLIO
- TABLE 83. EXACTECH, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 84. ZIMMER BIOMET HOLDING, INC.: KEY EXECUTIVES
- TABLE 85. ZIMMER BIOMET HOLDING, INC.: COMPANY SNAPSHOT
- TABLE 86. ZIMMER BIOMET HOLDING, INC.: OPERATING SEGMENTS
- TABLE 87. ZIMMER BIOMET HOLDING, INC.: PRODUCT PORTFOLIO
- TABLE 88. ZIMMER BIOMET HOLDING, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 89. ARTHREX, INC.: KEY EXECUTIVES
- TABLE 90. ARTHREX, INC.: COMPANY SNAPSHOT
- TABLE 91. ARTHREX, INC.: OPERATING SEGMENTS
- TABLE 92. ARTHREX, INC.: PRODUCT PORTFOLIO
- TABLE 93. ARTHREX, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 94. MEDTRONIC PLC: KEY EXECUTIVES
- TABLE 95. MEDTRONIC PLC: COMPANY SNAPSHOT
- TABLE 96. MEDTRONIC PLC: OPERATING SEGMENTS
- TABLE 97. MEDTRONIC PLC: PRODUCT PORTFOLIO
- TABLE 98. MEDTRONIC PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 99. ORGANOGENESIS INC: KEY EXECUTIVES
- TABLE 100. ORGANOGENESIS INC: COMPANY SNAPSHOT
- TABLE 101. ORGANOGENESIS INC: OPERATING SEGMENTS
- TABLE 102. ORGANOGENESIS INC: PRODUCT PORTFOLIO
- TABLE 103. ORGANOGENESIS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 104. KUROS BIOSCIENCES: KEY EXECUTIVES
- TABLE 105. KUROS BIOSCIENCES: COMPANY SNAPSHOT
- TABLE 106. KUROS BIOSCIENCES: OPERATING SEGMENTS
- TABLE 107. KUROS BIOSCIENCES: PRODUCT PORTFOLIO
- TABLE 108. KUROS BIOSCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1. GLOBAL SPINE BIOLOGICS MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF SPINE BIOLOGICS MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN SPINE BIOLOGICS MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALSPINE BIOLOGICS MARKET
- FIGURE 10. GLOBAL SPINE BIOLOGICS MARKET SEGMENTATION, BY PRODUCT
- FIGURE 11. SPINE BIOLOGICS MARKET FOR SPINAL ALLOGRAFTS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 12. SPINE BIOLOGICS MARKET FOR BONE GRAFT SUBSTITUTES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. SPINE BIOLOGICS MARKET FOR CELL-BASED MATRIX, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 14. GLOBAL SPINE BIOLOGICS MARKET SEGMENTATION, BY END USER
- FIGURE 15. SPINE BIOLOGICS MARKET FOR HOSPITALS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 16. SPINE BIOLOGICS MARKET FOR OUTPATIENT FACILITIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 17. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 18. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 19. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 20. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 21. COMPETITIVE DASHBOARD
- FIGURE 22. COMPETITIVE HEATMAP: SPINE BIOLOGICS MARKET
- FIGURE 23. TOP PLAYER POSITIONING, 2023
- FIGURE 24. STRYKER CORPORATION: NET SALES, 2021-2023 ($BILLION)
- FIGURE 25. STRYKER CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 26. STRYKER CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 27. NUVASIVE, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 28. NUVASIVE, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 29. NUVASIVE, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 30. ORTHOFIX: NET SALES, 2021-2023 ($BILLION)
- FIGURE 31. ORTHOFIX: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 32. ORTHOFIX: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 33. JOHNSON AND JOHNSON: NET SALES, 2021-2023 ($BILLION)
- FIGURE 34. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 35. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 36. EXACTECH, INC: NET SALES, 2021-2023 ($BILLION)
- FIGURE 37. EXACTECH, INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 38. EXACTECH, INC: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 39. ZIMMER BIOMET HOLDING, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 40. ZIMMER BIOMET HOLDING, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 41. ZIMMER BIOMET HOLDING, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 42. ARTHREX, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 43. ARTHREX, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 44. ARTHREX, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 45. MEDTRONIC PLC: NET SALES, 2021-2023 ($BILLION)
- FIGURE 46. MEDTRONIC PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 47. MEDTRONIC PLC: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 48. ORGANOGENESIS INC: NET SALES, 2021-2023 ($BILLION)
- FIGURE 49. ORGANOGENESIS INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 50. ORGANOGENESIS INC: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 51. KUROS BIOSCIENCES: NET SALES, 2021-2023 ($BILLION)
- FIGURE 52. KUROS BIOSCIENCES: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 53. KUROS BIOSCIENCES: REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook